Focused On-demand Library for H/ACA ribonucleoprotein complex subunit DKC1

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

O60832

UPID:

DKC1_HUMAN

Alternative names:

CBF5 homolog; Dyskerin; Nopp140-associated protein of 57 kDa; Nucleolar protein NAP57; Nucleolar protein family A member 4; snoRNP protein DKC1

Alternative UPACC:

O60832; F5BSB3; O43845; Q96G67; Q9Y505

Background:

H/ACA ribonucleoprotein complex subunit DKC1, also known as Dyskerin, plays a pivotal role in cellular processes, including ribosome biogenesis and telomere maintenance. It catalyzes the pseudouridylation of rRNA, a modification crucial for stabilizing rRNA structure and function. Dyskerin's involvement in cell adhesion and proliferation further underscores its multifaceted biological significance.

Therapeutic significance:

Dyskerin's mutation is directly linked to Dyskeratosis congenita and Hoyeraal-Hreidarsson syndrome, diseases characterized by bone marrow failure and developmental anomalies. Understanding Dyskerin's role could pave the way for innovative treatments targeting these genetic disorders, highlighting its therapeutic potential.